Volume 7.14 | Apr 14

Mesenchymal Cell News 7.14 April 14, 2015
Mesenchymal Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MESCN on Twitter
Pharmacological Inhibition of PRKG1 Enhances Bone Formation by Human Skeletal Stem Cells through Activation of RhoA-Akt Signaling
Scientists screened a library of kinase inhibitors to identify small molecules that enhance bone formation by human skeletal (stromal or mesenchymal) stem cells (hMSC). They identified H-8 as a potent enhancer of ex vivo osteoblast differentiation of hMSC, in a stage- and cell type-specific manner, without affecting adipogenesis or osteoclastogenesis. [Stem Cells] Abstract
Request Your Free Wallchart: Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology Collaboration)
PUBLICATIONS (Ranked by impact factor of the journal)
Activation of Non-Myogenic Mesenchymal Stem Cells during the Disease Progression in Dystrophic Dystrophin/Utrophin Knockout Mice
The authors showed that in contrast to myogenic progenitor cells (MPCs), non-myogenic mesenchymal stem cells (nmMSCs) become activated during disease progression in dystrophin/utrophin knockout (dKO) mice, displaying increased proliferation and differentiation potentials. They also found that after co-culturing the dKO-nmMSCs with dKO-MPCs, the myogenic differentiation potential of the dKO-MPCs was reduced. [Hum Mol Genet] Abstract

Mesenchymal Stem Cell Exosomes Induce the Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro
Scientists examined the role of mesenchymal stem cell (MSC) exosomes in wound healing. They found that MSCs exosomes ranged from 30 to 100-nm in diameter and internalization of MSC exosomes resulted in a dose-dependent enhancement of proliferation and migration of fibroblasts derived from normal donors and chronic wound patients. [Stem Cells Dev] Abstract

Mesenchymal Stem Cells Derived from Induced Pluripotent Stem Cells Combined with Low-Dose Rapamycin Induced Islet Allograft Tolerance via Suppressing Th1 and Enhancing Regulatory T Cell Differentiation
Investigators showed that mesenchymal stem cells derived from induced pluripotent stem cells (iPSC-MSCs) combined with rapamycin significantly prolonged islet allograft survival in the diabetic mice. Histopathological analysis revealed that iPSC-MSCs combined with rapamycin preserved the graft effectively, inhibited inflammatory cell infiltration and resulted in substantial release of insulin. [Stem Cells Dev] Abstract

Bone Marrow Mesenchymal Stem Cell Transplantation Retards the Natural Senescence of Rat Hearts
The authors investigated the antiaging properties of bone marrow mesenchymal stem cells and the underlying mechanism in a cellular model of cardiomyocyte senescence and a rat model of aging hearts. [Stem Cells Transl Med] Abstract | Press Release

Mesenchymal-Stem-Cell-Derived Exosomes Accelerate Skeletal Muscle Regeneration
Researchers investigated the role of mesenchymal stem cell (MSC) exosomes in skeletal muscle regeneration. MSC exosomes promotes myogenesis and angiogenesis in vitro, and muscle regeneration in an in vivo model of muscle injury. [FEBS Lett] Abstract

Icariin Induces Osteogenic Differentiation of Bone Mesenchymal Stem Cells in a MAPK-Dependent Manner
Effects of icariin on cell proliferation and osteogenic differentiation of rat bone mesenchymal stem cells were systematically evaluated. To characterize underlying mechanisms, its effects on mitogen-activated protein kinase signaling pathways were determined. [Cell Prolif] Abstract

Mesenchymal Stromal Cells Derived from Acute Myeloid Leukemia Bone Marrow Exhibit Aberrant Cytogenetics and Cytokine Elaboration
Researchers characterized the cytokine and gene expression profile, immunophenotype and cytogenetics of bone marrow-derived mesenchymal stromal cells (BM-MSCs) from acute myeloid leukemia (AML) patients compared to normal BM-MSCs from healthy donors. AML BM-MSCs showed decreased monocyte chemoattractant protein-1 levels compared to normal BM-MSCs. [Blood Cancer J] Full Article

Mesenchymal Stem Cells Facilitate In Vitro Development of Human Preantral Follicle
Scientists investigated whether mesenchymal stem cells (MSCs) could help to reconstruct a microenvironment to facilitate the in vitro follicle development. They showed human MSCs significantly promotes the survival rates, increases the growth velocity, and improves the viability of preantral follicles in a dose-dependent manner. [Reprod Sci] Abstract

FREE Webinar: Tips & Techniques for Highly Enriched Mouse MSC Cultures as Early as Passage 0.
Use of Mesenchymal Stem Cells for Therapy of Cardiac Disease
The authors review the biology of mesenchymal stem cells, their interaction with endogenous molecular and cellular pathways, and their modulation of immune responses. Additionally, they discuss factors that enhance their proliferative and regenerative ability and factors that may hinder their effectiveness in the clinical setting. [Circ Res] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.
BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase IIa Clinical Data
BrainStorm Cell Therapeutics Inc. announced results from its Phase IIa study of NurOwn® in amyotrophic lateral sclerosis. [Press release from BrainStorm Cell Therapeutics Inc. discussing research to be presented at the American Academy of Neurology Annual Meeting, Washington D.C.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
Anika Therapeutics Files IDE Application with U.S. FDA for Hyalofast®
Anika Therapeutics, Inc. announced that it has filed an investigational device exemption (IDE) with the U.S. Food and Drug Administration (FDA) to conduct a pivotal Phase III clinical trial for Hyalofast, a biodegradable, 3D, hyaluronic acid-based scaffold with autologous bone marrow aspirate concentrate. [Anika Therapeutics, Inc.] Press Release

Celgene and Mesoblast Enter into Equity Placement and Right of First Refusal Agreement to Certain Disease Fields
Mesoblast Limited announced that the company has entered into an agreement with US-based Celgene Corporation. Celgene has a six-month right of first refusal with respect to Mesoblast’s proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease, certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection. [Mesoblast Limited] Press Release

Bone Therapeutics Establishes US Subsidiary
Bone Therapeutics announced that it has established its US based subsidiary, Bone Therapeutics USA Inc. in Boston, Massachusetts. The establishment of the US headquarters is the first step for the company to move forward its US clinical trials program. [Bone Therapeutics S.A.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW ICTERM 2015: XIII International Conference on Tissue Engineering and Regenerative Medicine
July 20-21, 2015
Paris, France

Visit our events page to see a complete list of events in the mesenchymal cell community.
NEW PhD Position – Biomaterials & Regenerative Medicine (Florida Atlantic University)

NEW Faculty Positions – Stem Cell & Regenerative Medicine (The University of Texas Medical School at Houston)

NEW Postdoctoral Position – Stem Cells (Technion – Israel Institute of Technology)

NEW PhD Positions – Cartilage Regeneration in Joints and Intervertebral Disc Diseases (AO Research Institute)

Research Associate: Mesenchymal (STEMCELL Technologies Inc.)

Scientist – Myogenic Progenitor Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Fellowship – Hematology, Immunology, Stem Cell Transplantation, Cancer Therapeutics (The Research Institute at Nationwide Children’s Hospital)

Cell Culture Specialist – Mesenchymal Stem Cell and Neural Stem Cell Cultures (Tisch MS Research Center of New York)

Manufacturing Manager – Cell Therapy (Opexa Therapeutics)

Postdoctoral Fellow/Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us